Clinical Trials Logo
  1. Home
  2. PNH
  3. NCT05337683

A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean PNH Patients

PNH Clinical Trial

Official title:
A Retrospective Chart Review Study to Evaluate the Impact of Eculizumab in Korean Paroxysmal Nocturnal Hemoglobinuria Patients

Clinical Trial Summary

This study is a retrospective chart review study, and the main objective of this study is to identify the impact of eculizumab treatment and the improvement of complications before and after eculizumab treatment, and to evaluate the safety during the treatment and the clinical unmet needs during the treatment in PNH patients in real-world.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05337683
Study type Observational
Source Handok Inc.
Contact
Status Completed
Phase
Start date December 11, 2020
Completion date January 3, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Completed NCT02598583 - Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 1/Phase 2
Recruiting NCT05539248 - A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH Phase 1/Phase 2
Active, not recruiting NCT03460301 - Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH N/A
Completed NCT01412047 - Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study N/A
Completed NCT02605993 - Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Completed NCT05095168 - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects Phase 1
Active, not recruiting NCT04702568 - A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 2
Active, not recruiting NCT03531255 - Pegcetacoplan Long Term Safety and Efficacy Extension Study Phase 3
Completed NCT03593200 - A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH Phase 2
Completed NCT05884060 - Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones
Available NCT05982938 - Danicopan Early Access Program